The economic burden of end-stage renal disease with hyperphosphatemia: A study of Florida Medicaid

Keyphrases

• Florida 100%
• Medicaid 100%
• Economic Burden 100%
• End-stage Renal Disease 100%
• Hyperphosphatemia 100%
• Sevelamer 62%
• Cost Analysis 37%
• End-stage Renal Disease Patients 37%
• Calcium Acetate 37%
• Healthcare Utilization 25%
• Economic Impact 25%
• Comorbidity 25%
• Cost Drivers 25%
• Third-party Payers 25%
• Home Visits 25%
• Hospital Visits 25%
• Dialysis Facility 25%
• General Hospital 25%
• Medical Claims 25%
• Hypertension 12%
• Adverse Effects 12%
• Extracted Data 12%
• African American 12%
• Prescription Drug Costs 12%
• Health Care Costs 12%
• Inclusion Criteria 12%
• Healthcare 12%
• High Cost 12%
• Pharmacy 12%
• Congestive Heart Failure 12%
• Exclusion Criteria 12%
• Inpatient Visits 12%
• Nursing Homes 12%
• Emergency Room 12%
• Hospital Costs 12%
• Payer Perspective 12%
• Prescription Drugs 12%
• High-cost Drugs 12%
• Racial Groups 12%
• Preventive Measures 12%
• Anemia 12%
• Direct Costs 12%
• Related Services 12%
• Cost of Illness 12%
• Medicaid Database 12%
• Medical Services 12%
• Ambulance Service 12%
• Hypercalcemia 12%
• Phosphate Binder 12%
• Outpatient Cost 12%
• Prescription Claims 12%
• Hemophilia 12%
• Patient Inclusion 12%
• US11 12%

Pharmacology, Toxicology and Pharmaceutical Science

• End Stage Renal Disease 100%
• Hyperphosphatemia 100%
• Sevelamer 62%
• Calcium Acetate 37%
• Hemodialysis 25%
• Comorbidity 25%
• Adverse Event 12%
• Disease 12%
• HIV 12%
• Retrospective Study 12%
• Congestive Heart Failure 12%
• Prescription Medication 12%
• Anemia 12%
• Phosphate Binding Agent 12%
• Hypercalcaemia 12%
• Haemophilia A 12%